Renin inhibitors are antihypertensive drugs which block the first step in the renin-angiotensin system. Their mechanism of action differs from that of angiotensin converting enzyme inhibitors and angiotensin receptor antagonists, but like these drugs, renin inhibitors interrupt the negative feedback effects of angiotensin II on renin secretion. This increases renin concentrations which may attenuate the inhibition of the reninangiotensin system by these therapies. Renin inhibitors may interfere with measurements of renin in plasma.
Introduction
Drugs that inhibit the renin-angiotensin system, such as angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists, have proven value for the treatment of hypertension, heart failure and renal disease. They reduce the rates of death, myocardial infarction and stroke in a broad range of patients at high risk, but do not control the blood pressure in all cases. This led to research into inhibiting the renin-angiotensin system at its first step -the production of angiotensin I.
Physiology
Renin is an enzyme produced from the inactive protein, prorenin. The release of renin from the juxtaglomerular cells of the kidney is controlled by several mechanisms. These include the sympathetic nervous system, salt and fluid balance, blood pressure, and negative feedback by angiotensin II. Renin cleaves circulating angiotensinogen to form angiotensin I (Fig. 1 ).
This inactive decapeptide is subsequently cleaved by ACE to produce the octapeptide angiotensin II. Although other bioactive angiotensin peptides are produced from angiotensin I and II, angiotensin II is the main bioactive angiotensin peptide.
Two different receptors mediate the actions of angiotensin II.
These are the type 1 (AT 1 ) and the type 2 (AT 2 ) receptors (Fig. 1) .
Stimulation of the AT 1 receptor increases arterial tone and aldosterone secretion. Angiotensin II therefore plays an essential role in blood pressure, and fluid and electrolyte homeostasis.
However, this role is much diminished in people consuming a Western diet with an excessive salt content. In these people, even 'normal' concentrations of angiotensin II may play a role in hypertension and in cardiovascular and renal disease.
Angiotensin-(1-7), a heptapeptide, is a metabolite of angiotensins I and II. Both angiotensin-(1-7), acting through its own receptor, and angiotensin II, acting on the AT 2 receptor, may counterbalance some of the effects of angiotensin II stimulating the AT 1 receptor.
The kidney is not the only organ which produces prorenin, and a receptor which binds renin and prorenin has been discovered. 
Inhibitors of the renin-angiotensin system
The therapeutic benefits of inhibiting the renin-angiotensin system are attributed primarily to reduced stimulation of the AT 1 receptor. This can be achieved by either reducing angiotensin II concentrations or blocking the AT 1 receptor, although other mechanisms may contribute (Table 1) .
Beta blockers inhibit renin release from the kidney and were the original renin-angiotensin system inhibitors. Reduced renin release leads to reduced concentrations of angiotensin I and II, which may contribute to the benefits of beta blockade in heart failure. 1 In contrast to beta blockers, ACE inhibitors, angiotensin receptor antagonists and renin inhibitors cause an increase in renin release. This is because by reducing AT 1 receptor stimulation they interrupt the negative feedback-mediated regulation of renin release. The combination of an ACE inhibitor, angiotensin receptor antagonist or renin inhibitor with another drug from these groups, or with a diuretic, markedly amplifies the increase in renin concentrations. The increase in renin concentrations may be as much as 100-fold, which then offsets the inhibition of the renin-angiotensin system by these antihypertensive drugs.
This may attenuate any reduction in blood pressure.
ACE inhibitors, angiotensin receptor antagonists and renin
inhibitors have different effects on the concentrations of angiotensin peptides and bradykinin (a vasodilator) ( Table 1) . 
Clinical pharmacology of renin inhibitors
Several renin inhibitors were abandoned because of problems in development. Aliskiren is the first renin inhibitor for which we have extensive information about clinical pharmacology.
Other renin inhibitors in clinical development are likely to have different pharmacologies.
Aliskiren is a competitive renin inhibitor which binds to the active site of the enzyme. It is a rather hydrophilic molecule with high aqueous solubility. 4 The distribution volume of intravenously administered aliskiren is 135 L in normal volunteers, indicating extensive tissue uptake of the drug. 5 The absorbed fraction of orally administered aliskiren is approximately 5%. This low oral bioavailability is compensated for by a long plasma half-life of 34-41 hours, and steady-state plasma aliskiren concentrations are achieved after 5-8 days of daily dosing. 6 Approximately 90% of the drug is excreted unchanged in the faeces. 7 The long plasma half-life and very low urinary excretion (< 1%) 6, 7 suggest extensive binding of the drug to plasma proteins. 5 Protein binding accounts for the discrepancy between the concentration of aliskiren required for 50% inhibition of pure renin and that for inhibition of renin in plasma. The concentration (IC 50 ) required was 0.6 nmol/L for pure renin versus 10-14 nmol/L for renin in human plasma. 5 This suggests that more than 90% of plasma aliskiren is bound to plasma 
Conclusion
Renin inhibitors represent an alternative strategy for inhibiting the renin-angiotensin system. They have a mechanism of action different from that of ACE inhibitors and angiotensin receptor antagonists. Whether renin inhibitors offer therapeutic benefits beyond those provided by ACE inhibitor and angiotensin receptor antagonist therapies will require their direct comparison in clinical outcome studies.
